-
公开(公告)号:US20220024981A1
公开(公告)日:2022-01-27
申请号:US17296679
申请日:2019-11-26
Applicant: Novartis AG
Inventor: Alec Nathanson FLYER , Andrei Alexandrovich GOLOSOV , Philipp GROSCHE , Ian LEWIS , Eugene Yuejin LIU , Andreas MARZINZIK , Lauren Gilchrist MONOVICH , Johannes OTTL , Tajesh Jayprakash PATEL , Patrick Crawford REID , Mohindra SEEPERSAUD
Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are described herein.
-
公开(公告)号:US20220340573A1
公开(公告)日:2022-10-27
申请号:US17805487
申请日:2022-06-06
Applicant: Novartis AG
Inventor: Kelly D. BOSS , Yi FAN , Alec Nathanson FLYER , Declan HARDY , Zhihong HUANG , Kathryn Taylor LINKENS , Jon Christopher LOREN , Fupeng MA , Valentina MOLTENI , Duncan SHAW , Jeffrey SMITH , Catherine Fooks SOLOVAY
IPC: C07D471/10 , A61P27/04 , C07D413/06 , C07D413/14 , C07D491/107
Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I′), or pharmaceutical composition described herein.
-
公开(公告)号:US20200164024A1
公开(公告)日:2020-05-28
申请号:US16695843
申请日:2019-11-26
Applicant: NOVARTIS AG
Inventor: Karin BRINER , Brian Addison DECHRISTOPHER , Alec Nathanson FLYER , Andrei Alexandrovich GOLOSOV , Philipp GROSCHE , Eugene Yuejin LIU , Justin Yik Ching MAO , Lauren Gilchrist MONOVICH , Tajesh Jayprakash PATEL , Carina Cristina SANCHEZ , Liansheng SU , Lihua YANG , Rui ZHENG
Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
-
公开(公告)号:US20230089867A1
公开(公告)日:2023-03-23
申请号:US17296895
申请日:2019-11-26
Applicant: Novartis AG
Inventor: Christopher BECKER , Brian Addison DECHRISTOPHER , Alec Nathanson FLYER , Adam FRIEDMAN , Christian GAMPE , Andrei Alexandrovich GOLOSOV , Philipp GROSCHE , Tyler HARRISON , Qian LIU , Eugene Yuejin LIU, I , Justin Yik Ching MAO , Lauren Gilchrist MONOVICH , Tajesh Jayprakash PATEL , Carina Cristina SANCHEZ , Liansheng SU , Lihua YANG , Rui ZHENG
IPC: C07K7/56
Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein X1, R1, R2, R3, R4, R5, R6, R6′, R7, R7′, R8, R9, R9′, R10, R11, R12, and n are described herein.
-
公开(公告)号:US20220064164A1
公开(公告)日:2022-03-03
申请号:US17101510
申请日:2020-11-23
Applicant: NOVARTIS AG
Inventor: Kelly D. BOSS , Yi FAN , Alec Nathanson FLYER , Declan HARDY , Zhihong HUANG , Kathryn Taylor LINKENS , Jon Christopher LOREN , Fupeng MA , Valentina MOLTENI , Duncan SHAW , Jeffrey SMITH , Catherine Fooks SOLOVAY
IPC: C07D471/10 , C07D413/14 , C07D413/06 , C07D491/107 , A61P27/04
Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I′), or pharmaceutical composition described herein.
-
公开(公告)号:US20210252103A1
公开(公告)日:2021-08-19
申请号:US17200471
申请日:2021-03-12
Applicant: NOVARTIS AG
Inventor: Karin BRINER , Brian Addison DECHRISTOPHER , Alec Nathanson FLYER , Andrei Alexandrovich GOLOSOV , Philipp GROSCHE , Eugene Yuejin LIU , Justin Yik Ching MAO , Lauren Gilchrist MONOVICH , Tajesh Jayprakash PATEL , Liansheng SU , Lihua YANG , Rui ZHENG
Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
-
-
-
-
-